Effects of technetium-99 methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with Graves ophthalmopathy

Nuclear Medicine Communications

Volumn 32, Issue 2, 2011, Pages 142-146

  Shu Xun, Yan ^a   Ying, Wang ^a   Gui Jun, Peng ^a   Xin Ping, Lu ^a   Yu, Fu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

99Tc MDP; cytokine; Graves ophthalmopathy; retro ocular fibroblasts; technetium 99 methylenediphosphonate

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; MEDRONATE TECHNETIUM TC 99M; THYMIDINE; TRITIUM; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CELL PROLIFERATION; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; RADIOIMMUNOASSAY; SKIN FIBROBLAST;

ADULT; CASE-CONTROL STUDIES; CELL PROLIFERATION; CYTOKINES; EYE; FIBROBLASTS; GENE EXPRESSION REGULATION; GRAVES OPHTHALMOPATHY; HLA-DR ANTIGENS; HUMANS; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE-1; MALE; SKIN; TECHNETIUM TC 99M MEDRONATE;

EID: 78650957872     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834121cb     Document Type: Article

References (23)

1. Daroszewski J, Rybka J, Gamian A. Glycosaminoglycans in the pathogenesis and diagnostics of Gravess ophthalmopathy. Postepy Hig Med Dosw 2006; 60:370-373.
2. Modi NC, James J, Sleep T. Thyroid eye disease. J Perioper Pract 2009; 9:282-286.
3. Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves disease, and thyroid-associated ophthalmopathy. Thyroid 2008; 9:953-958.
4. Ponto KA, Pitz S, Mann WJ,Weber MM, Pfeiffer N, Kahaly GJ. Management of Graves orbitopathy: evidence-based recommendations. Dtsch Med Wochenschr 2009; 49:2521-2524.
5. Yarman S, Oguz F, Carin M. HLA-DRB1*03 is a susceptibility gene in patients with Graves disease with and without ophthalmopathy. Int J Immunogenet 2007; 1:23-25.
6. Eckstein AK, Johnson KT, Thanos M, Esser J, Ludgate M. Current insights into the pathogenesis of Graves orbitopathy. Horm Metab Res 2009; 6:456-464.
7. Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock S, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci 2009; 5:2262-2268.
8. Luo H, Zuo XX, Xie YL, Zhou YL, Wang YP. Study of B(99)Tc-MDP treatment on type II collagen induced arthritis in rats and influence on the serum IL-1b. J Clin Res 2006; 9:1417-1419.
9. Wu YG, Ma QL, Liu GF. Effect of 99Tc-MDP on cytokine production by peripheral blood mononuclear cells of patients with rheumatoid arthritis. Hu Nan Yi Ke Da Xue Xue Bao She Ke Ban 2002; 2:173-175.
10. Mu R, Chen S, Li ZG, Ren LM. Therapeutic effect ofB(99m)Tc-MDP and its role in proinflammatory cytokines in rheumatoid arthritis. Chin J Rheumatol 2004; 1:39-41.
11. Fu Q, Shi YZ, Luo H, You YH, Zuo XX. The activation of mitogen-activated protein kinase pathway in peripheral blood mononuclear cells of rheumatoid arthritis patients and the regulation of B(99)Tc-MDP on it. Chin J Rheumatol 2006; 3:149-153.
12. Xie YL, Luo H, Zuo XX, Zhou YO, Fu Q. Study of the treatment of B(99)Tcmethylene diphosphonate on type II collagen induced arthritis in rats and its effect on the synovial matrix metalloproteinase-3 and tissue inhibitor of matrix metalloproteinase-1. Chin J Rheumatol 2006; 7:406-409.
13. Wu YG, Ma QL, Liu GF, He JJ, Su JZ, Zhi K. Effects of 99Tc-MDP on the cultured retroocular fibroblast to stimulated by IL-1b. Chi J Mod Med 2002; 11:62-63.
14. Yan SX, Wang Y. Inhibitory effects of triptolide on IFN-g induced HLA-DR, ICAM-1, CD40 expression on retroocular fibroblasts derived from patients with Graves ophthalmopathy. Clin Exp Ophthalmol 2006; 3:265-271.
15. Gao KJ, Ye ZW, Li W, Mei XG,Wang JH. Research the value of the 99Tc-MDP for animal model osteogenesis. Chin J Pract Med 2006; 10:1084-1086.
16. Yang NP, Zuo C, Chen YT, Li JT,Wang L. Clinical application in the therapy of rheumatoid arthritis with Technetium 99mTc methylenediphosphonate injection. Chin J Rheumatol 2003; 12:752-754.
17. Zhang MM, Liu ZH, Wu NB, Guo Z, Zhang CX, Tang P. The regulation of YunKe in bone metabolism of postmenopausal osteoporosis. Chin J Osteoporos 2008; 9:659-660.
18. Wang CX, Zhang LM. Clinical analysis of ankylosing spondylitis treated with Yunke. J Taishan Med Coll 2007; 8:640-642.
19. Ding HP. Curative effectiveness of MDP in the treatment of Graves eye disease and nursing care. J Nurs Sci 2003; 8:625-626.
20. Zhao YS, Huang TJ, Zhao CW, Lei Y, Yi W. The clinic observation of 99Tc-MDP therapy in Graves ophthalmopathy. J Qiqihar Med Coll 2004; 5:483-484.
21. Wang RF, Tan J, Zhang GZ, Lei L. The effect of 99Tc-methylene diphosphonate on Graves ophthalmopathy treated by 131I. Chin J Postgrad Med 2009; 12:27-29.
22. Bretscher P. The two-signal model of lymphocytes activation twenty-one year later. Immunol Today 1992; 2:74-76.
23. Makgoba MW, Sanders ME, Ginther Luce GE. ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature 1988; 331:86-88.